5.84
price up icon0.34%   0.02
pre-market  Pre-market:  6.27   0.43   +7.36%
loading
Verastem Inc stock is traded at $5.84, with a volume of 825.78K. It is up +0.34% in the last 24 hours and up +4.38% over the past month.
See More
Previous Close:
$5.82
Open:
$5.75
24h Volume:
825.78K
Relative Volume:
0.67
Market Cap:
$299.65M
Revenue:
$3.64M
Net Income/Loss:
$-87.37M
P/E Ratio:
-1.4209
EPS:
-4.11
Net Cash Flow:
$-86.46M
1W Performance:
-8.75%
1M Performance:
+4.38%
6M Performance:
+100.69%
1Y Performance:
-49.31%
1-Day Range:
Value
$5.4601
$6.09
1-Week Range:
Value
$5.4601
$6.89
52-Week Range:
Value
$2.10
$13.52

Verastem Inc Stock (VSTM) Company Profile

Name
Name
Verastem Inc
Name
Phone
(781) 292-4200
Name
Address
117 KENDRICK STREET, NEEDHAM, MA
Name
Employee
0
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
VSTM's Discussions on Twitter

Compare VSTM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VSTM
Verastem Inc
5.84 299.65M 3.64M -87.37M -86.46M -4.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Verastem Inc Stock (VSTM) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-24-25 Reiterated H.C. Wainwright Buy
Dec-31-24 Reiterated BTIG Research Buy
Sep-30-24 Initiated Guggenheim Buy
Nov-21-23 Resumed BTIG Research Buy
Sep-27-23 Initiated B. Riley Securities Buy
Jun-15-23 Upgrade Mizuho Neutral → Buy
Sep-07-22 Resumed Alliance Global Partners Buy
Apr-29-22 Resumed Cantor Fitzgerald Overweight
Apr-14-22 Initiated RBC Capital Mkts Outperform
Mar-09-22 Initiated Truist Buy
Jul-01-21 Initiated Alliance Global Partners Buy
May-24-21 Upgrade BTIG Research Neutral → Buy
Jun-20-19 Downgrade BTIG Research Buy → Neutral
May-10-19 Downgrade Raymond James Outperform → Mkt Perform
Jul-13-18 Initiated BTIG Research Buy
May-02-18 Initiated Seaport Global Securities Buy
Mar-08-18 Initiated B. Riley FBR, Inc. Buy
Sep-07-17 Reiterated H.C. Wainwright Buy
Apr-13-17 Initiated Oppenheimer Outperform
Mar-24-17 Reiterated H.C. Wainwright Buy
Sep-29-15 Downgrade Cantor Fitzgerald Buy → Hold
Sep-29-15 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-29-15 Downgrade Jefferies Buy → Hold
Sep-29-15 Downgrade Raymond James Strong Buy → Outperform
Sep-28-15 Downgrade Mizuho Buy → Neutral
Sep-28-15 Downgrade ROTH Capital Buy → Neutral
Sep-09-15 Initiated Raymond James Strong Buy
May-12-15 Reiterated UBS Buy
Apr-08-15 Initiated H.C. Wainwright Buy
Jan-23-15 Reiterated ROTH Capital Buy
Jul-08-14 Resumed Oppenheimer Perform
Feb-11-14 Initiated Mizuho Buy
View All

Verastem Inc Stock (VSTM) Latest News

pulisher
Apr 02, 2025

Verastem Oncology Reports Progress in Cancer Treatments - TipRanks

Apr 02, 2025
pulisher
Mar 28, 2025

Verastem (NASDAQ:VSTM) Upgraded at StockNews.com - MarketBeat

Mar 28, 2025
pulisher
Mar 27, 2025

Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 25, 2025

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 - Yahoo Finance

Mar 25, 2025
pulisher
Mar 25, 2025

Revolutionary Cancer Drug Achieves Complete Response in Colorectal Cancer Study - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

Verastem CFO Daniel Calkins sells shares worth $630 - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Verastem CFO Daniel Calkins sells shares worth $630 By Investing.com - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

H.C. Wainwright lifts Verastem stock price target to $10 By Investing.com - Investing.com Canada

Mar 24, 2025
pulisher
Mar 24, 2025

Guggenheim lifts Verastem stock target to $14, maintains buy By Investing.com - Investing.com Canada

Mar 24, 2025
pulisher
Mar 24, 2025

H.C. Wainwright lifts Verastem stock price target to $10 - Investing.com India

Mar 24, 2025
pulisher
Mar 23, 2025

Royal Bank of Canada Lowers Verastem (NASDAQ:VSTM) Price Target to $14.00 - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

RBC Cuts Price Target on Verastem to $14 From $16, Maintains Outperform Rating -March 21, 2025 at 08:40 am EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

BTIG maintains $20 target, Buy rating on Verastem stock By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 21, 2025

Verastem: Q4 Earnings Snapshot - Midland Daily News

Mar 21, 2025
pulisher
Mar 20, 2025

Verastem director Brian Stuglik sells shares worth $4,121 By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem Unveils Strategic Plans in New Presentation - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem, Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem Inc. (VSTM) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates - Bluefield Daily Telegraph

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem director Robert Gagnon sells shares worth $1,973 By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 20, 2025
pulisher
Mar 20, 2025

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Verastem CEO sells shares worth $1,695 By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Verastem director Robert Gagnon sells shares worth $1,973 - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Verastem director Brian Stuglik sells shares worth $4,121 - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Verastem (NASDAQ:VSTM) Stock Passes Above 200-Day Moving Average – Here’s Why - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

Mar 18, 2025
pulisher
Mar 14, 2025

Verastem Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView

Mar 14, 2025
pulisher
Mar 13, 2025

Verastem to Present at Keystone Symposia on PI3 Kinase - AOL.com

Mar 13, 2025
pulisher
Mar 11, 2025

Verastem: Upcoming PDUFA, But I Remain Cautious (NASDAQ:VSTM) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 11, 2025

Rhumbline Advisers Acquires 10,352 Shares of Verastem, Inc. (NASDAQ:VSTM) - Defense World

Mar 11, 2025
pulisher
Mar 08, 2025

Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve

Mar 08, 2025
pulisher
Mar 08, 2025

Why the Global Cancer Market Could Surpass $900 Billion—And the Stocks Leading the Charge - Morningstar

Mar 08, 2025
pulisher
Mar 06, 2025

Verastem (VSTM) Expected to Announce Earnings on Thursday - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Objective long/short (VSTM) Report - Stock Traders Daily

Mar 06, 2025
pulisher
Mar 05, 2025

Verastem Inc (NASDAQ: VSTM) Stock Forecast: Bearish Expectations Portend -120.34% Downside In 2025 - Stocks Register

Mar 05, 2025
pulisher
Mar 04, 2025

Verastem (NASDAQ:VSTM) Stock Price Passes Above 200 Day Moving Average – Should You Sell? - Defense World

Mar 04, 2025
pulisher
Feb 23, 2025

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of “Buy” by Brokerages - Defense World

Feb 23, 2025
pulisher
Feb 20, 2025

Verastem Oncology Announces Multiple Data Presentations At Society Of Gynecologic Oncology 2025 Annual Meeting On Women's Cancer - Marketscreener.com

Feb 20, 2025
pulisher
Feb 20, 2025

Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer - Business Wire

Feb 20, 2025
pulisher
Feb 19, 2025

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag - MSN

Feb 19, 2025
pulisher
Feb 13, 2025

When the Price of (VSTM) Talks, People Listen - Stock Traders Daily

Feb 13, 2025
pulisher
Feb 10, 2025

Financial Snapshot: Analyzing Verastem Inc (VSTM)’s Key Ratio Metrics - The Dwinnex

Feb 10, 2025
pulisher
Feb 08, 2025

Verastem Inc (NASDAQ: VSTM) Shares Fall By -4.77 Percent In The Past Week, But How Long Will It Last? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 06, 2025

The time has not yet come to remove your chips from the table: Verastem Inc (VSTM) - SETE News

Feb 06, 2025

Verastem Inc Stock (VSTM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):